Qventus Valuation, Funding & Investors

Qventus is valued at $400M as of January 2025.

Last Qventus valuation

$400M

Series D · Jan 2025

Last Qventus funding round

$85M

Series D · Jan 2025

Cumulative funding Qventus raised

$183M

across 6 funding rounds

Key investors in Qventus

  • Bessemer Venture Partners
  • Norwest
  • Mayfield Fund
  • Y Combinator
  • StartX (Stanford-StartX Fund)
  • Think + Ventures

Qventus Overview

About Qventus

Qventus is a provider of AI-powered automation platforms for healthcare operations in the United States. Its solutions optimize patient flow, reduce staff burdens, and unlock capacity at hospitals and health systems through intelligent resource management.


Founded

2012

HQ

United StatesSan Francisco, CA

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Valuation

$400M (Jan 2025)

Qventus Valuation

Qventus is currently valued at $400M, based on its Series D in January 2025.

The $85M round was led by KKR, with participation from Northwestern Medicine Mansueto Innovation Institute, Bessemer Venture Partners, HonorHealth and Allina Health.

Qventus' valuation has grown 24x from $17M at its seed round in October 2015 to $400M in January 2025, across 3 priced rounds.

Qventus valuation by funding round

Qventus valuation by funding round
DateStageValuation
Jan 2025Series D$400M
Feb 2022Undisclosed stage$200M
Oct 2015Seed$17M

Qventus Funding History

Qventus has raised a total of $183M across 6 funding rounds.

Qventus' first fundraising round was a $2M seed round in October 2015. The most recent completed round was a $85M Series D in January 2025.

Qventus funding rounds

Qventus funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jan 2025Series DKKR (lead); Northwestern Medicine Mansueto Innovation Institute; Bessemer Venture Partners; HonorHealth; Allina Health$85M$400MQventus is an AI-first care operations automation platform provider, specializing in inpatient and outpatient solutions that integrate with electronic health records (EHRs) using generative AI, machine learning, and behavioral science to predict bottlenecks, recommend remedies, and automate processes like surgical growth and inpatient capacity management. The company, founded over a decade ago and based in Mountain View or Palo Alto, CA, serves health systems, independent hospitals, and academic medical centers, delivering average over 10x ROI for clients and earning top KLAS scores of 92.5% in capacity management as of November 2024, with 100% customer retention in long-term plans, plus a Frost & Sullivan award. On January 13, 2025, Qventus closed a $105 million Series D round ($85 million equity + $20 million optional debt), led by KKR from its tech growth equity fund, with participation from prior investor Bessemer Venture Partners and new strategic health system investors Northwestern Medicine, HonorHealth, and Allina Health. This 'mega-round' doubled lifetime funding to $200 million from prior $95 million, at a valuation over $400 million (up from ~$200 million in 2022), though the company was not actively seeking capital. Funds will accelerate development and expansion of AI Operational Assistants across more care settings and use cases. CEO Mudit Garg highlighted the unsolicited KKR interest due to Qventus' decade-long proprietary data engine, workflow expertise, and EHR integrations amid rising AI healthcare momentum. The round underscores investor enthusiasm for operational AI in healthcare, following big raises by peers like Innovaccer ($275M), Hippocratic ($141M), and Cera ($150M). Qventus' traction includes global team expansion, partner growth, and highest KLAS ratings, positioning it as a leader despite challenges like EHR integration and regulation.
Aug 2022Strategic investmentFroedtert ThedaCare Health (lead)$3M-Qventus develops AI-based care operations automation software for health systems to optimize inpatient, perioperative, emergency department, and command center operations. The company raised $3 million in a corporate round in August 2022 led by Froedtert ThedaCare Health to develop new AI solutions and expand market presence. This followed a $50 million growth capital round in 2022 led by THL with participation from ThedaCare, Premier Inc., Bessemer Venture Partners, Mayfield Fund, and Norwest Venture Partners. Qventus partners with leading health systems including Boston Medical Center, HonorHealth, M Health Fairview, Mercy, and Saint Luke’s Health System. In 2021, the platform automated access and patient flow for over 2 million patient encounters, eliminating over 200 years of excess days and delivering a 10X return on investment. Outcomes include 30-50% fewer excess days, one full day reduction in length of stay, and over 2 additional cases per operating room per month. Subsequent funding included a $105 million Series D in January 2025 led by KKR with $85 million equity and $20 million optional debt at over $400 million valuation, bringing total funding over $200 million. A prior 2022 valuation was around $200 million, with four-fold customer base growth and three-fold core business growth since then.
Feb 2022Undisclosed stagePremier Inc (lead); THL (lead); Norwest; Bessemer Venture Partners; Froedtert ThedaCare Health; Mayfield Fund$50M$200MQventus develops AI-powered operational platforms for hospitals and health systems, integrating with electronic health records (EHRs) to predict issues, orchestrate frontline actions, and drive improvements in inpatient capacity, surgical scheduling, and other areas. The company raised a Series C round on February 28, 2022, with participation from investors including Bessemer Venture Partners, Froedtert ThedaCare Health, Mayfield Fund, Norwest, Premier Inc., and THL, where Premier Inc. and THL were leads. Valuation details confirm a post-money valuation around $200 million for this 2022 round. Post-2022, Qventus continued growth with a corporate minority round of $3 million in August 2022 led by Froedtert ThedaCare Health to develop AI solutions and expand market presence. By January 2025, Qventus secured a $105 million Series D ($85 million equity + $20 million debt) led by KKR, with Bessemer and strategic health systems like Northwestern Medicine, HonorHealth, and Allina Health, at over $400 million valuation—more than double the 2022 figure. This reflects four-fold customer base growth, 120% net retention, and three-fold core business growth since 2022, positioning Qventus close to breaking even. Traction highlights include eliminating over 36,000 excess inpatient days saving millions, and in 2024, its Surgical Growth solution generating $95 million in annualized contribution margin across over 500 million surgeries with 35% more robotic cases. Qventus earned a 92.5% KLAS score in capacity management and Frost & Sullivan's Best Practices award for 10x average ROI. Total funding reached about $203 million by 2025, underscoring its leadership in AI healthcare operations amid rising investor interest.
May 2018Series BBessemer Venture Partners (lead); New York Presbyterian Ventures (lead); Norwest; Think + Ventures; Mayfield Fund$30M--
Nov 2016Series AMayfield Fund (lead); Norwest (lead); Y Combinator; The Valley Fund; StartX (Stanford-StartX Fund)$13M--
Oct 2015SeedAcorn Pacific Ventures; Y Combinator; Wally Wang; Think + Ventures; FundersClub; The Valley Fund; Pegasus Tech Ventures; StartX (Stanford-StartX Fund)$2M$17M-

Who has invested in Qventus?

19 investors have backed Qventus across its funding rounds, including Bessemer Venture Partners, Norwest, Mayfield Fund, Y Combinator, StartX (Stanford-StartX Fund) and Think + Ventures.

Lead investors include KKR, Froedtert ThedaCare Health, Premier Inc, THL, Bessemer Venture Partners and 3 other investors.


Qventus Investors

Investors in Qventus by funding rounds participated
InvestorHQRoundsRoleFirst check
NorwestUnited StatesSan Francisco, CA3LeadNov 2016
Bessemer Venture PartnersUnited StatesSan Francisco, CA3LeadMay 2018
Mayfield FundUnited StatesUnited States3LeadNov 2016
Y CombinatorUnited StatesSan Francisco, CA2ParticipantOct 2015
Think + VenturesUnited StatesSan Francisco, CA2ParticipantOct 2015
Froedtert ThedaCare HealthUnited StatesGreen Bay, WI2LeadFeb 2022
The Valley FundUnited StatesSan Francisco, CA2ParticipantOct 2015
StartX (Stanford-StartX Fund)United StatesSan Francisco, CA2ParticipantOct 2015
KKRUnited StatesNew York City, NY1LeadJan 2025
Premier IncUnited StatesCharlotte, NC1LeadFeb 2022
Acorn Pacific VenturesUnited StatesSan Jose, CA1ParticipantOct 2015
Wally WangUnited StatesUnited States1ParticipantOct 2015
Northwestern Medicine Mansueto Innovation InstituteUnited StatesUnited States1ParticipantJan 2025

This data is available for Pro users. Sign up to see all 19 Qventus investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Qventus Competitors

Qventus competitors include listed companies like Yidu Tech and Ever Fortune.AI, and private ones like Heidi Health, Plenful, Suki and Snapsheet.

Public and private companies comparable to Qventus
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Heidi HealthAustraliaSydneyPrivate$15M-$465M31.0x
PlenfulUnited StatesSan Francisco, CAPrivate--$487M-
SukiUnited StatesSan Francisco, CAPrivate$105M-$500M-
SnapsheetUnited StatesChicago, ILPrivate$37M-$300M8.1x
Yidu TechChinaChinaPublicly listed$122M($4M)$449M1.2x
Ever Fortune.AITaiwanTaiwanPublicly listed$12M$4M$158M-

Qventus Public Comps

Qventus is still privately-owned, but its public comps include Ropeok Technology Group, Winner Technology, Nanjing Medlander Medical, DSC Holdings, Artrya, Simulations Plus, Cerence, Optima Health, Kneat and Yidu Tech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Ropeok Technology Group$23M($28M)18.6x-(15.2x)-
Winner Technology$46M($7M)9.0x-(60.9x)-
Nanjing Medlander Medical$64M$20M4.9x-15.8x-
DSC Holdings$101M($10M)3.3x-(34.3x)-
Artrya$20K($19M)18657.4x440.3x(19.8x)(22.4x)
Simulations Plus$79M($62M)4.1x3.9x(5.2x)13.9x
Cerence$252M$8M1.7x1.4x52.9x6.2x
Optima Health$162M$20M3.1x2.3x24.4x15.4x

This data is available for Pro users. Sign up to see all Qventus competitors and their valuation data.

Start Free Trial

Common questions about Qventus

When was Qventus founded?Qventus was founded in 2012.
Where is Qventus headquartered?Qventus is headquartered in San Francisco, CA, United States.
Is Qventus publicly listed?No, Qventus is a private, VC-backed company.
What is Qventus' valuation?Qventus was last valued at $400M in its Series D in January 2025.
How much funding has Qventus raised?Qventus has raised $183M across 6 funding rounds.
What was Qventus' last funding round?Qventus' last funding round was a $85M Series D in January 2025, led by KKR.
Who are Qventus' investors?Qventus' investors include Norwest, Bessemer Venture Partners, Mayfield Fund, Y Combinator, Think + Ventures, Froedtert ThedaCare Health, The Valley Fund, StartX (Stanford-StartX Fund), KKR, Premier Inc and 9 others.
Which companies are comparable to Qventus?Companies comparable to Qventus include Heidi Health, Plenful, Suki, Snapsheet, Yidu Tech and Ever Fortune.AI.

See companies similar to Qventus

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial